Navigation Links
Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
Date:11/19/2013

BOSTON, Nov. 19, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics has initiated dosing in a Phase 2, randomized controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly known as "double chin." XAF5 Gel is a proprietary skin formulation of a compound already known to reduce fat around the human eye.  Study participants are applying XAF5 Gel or placebo once a night to skin under the chin.

"Patients are increasingly interested in non-invasive therapies to rejuvenate the face," said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Topokine's Scientific Board of Advisors.  "If approved, XAF5 Gel would provide a convenient topical medication that reduces submental fat."

XAF5 is a small molecule that induces a G protein-coupled cascade in adipocytes to reduce cellular lipid content and differentiation.  Daily administration of XAF5 reduces fat around the human eye and in five laboratory models.  The technology was first conceived by ophthalmologists at the Massachusetts Eye and Ear Infirmary / Harvard Medical School Department of Ophthalmology.

The Phase 2 study follows positive data from a 6-week Phase 1 clinical trial completed in April 2013.  In that randomized, double-blind, placebo-controlled study, 32 healthy men and women applied XAF5 Gel or placebo once a night to a 100 cm2 area of abdominal skin.  The study met its pre-specified primary safety and tolerability endpoint at all doses.  The only side effects were mild, temporary skin redness or itch, which occurred at similar rates with placebo.  Exploratory CT scans showed a dose-dependent reduction in fat volume under treated skin as compared to contralateral untreated skin.

 "We are excited to advance our XAF5 Gel program into Phase 2," said Topokine's Chief Scientific Officer, Michael Si
'/>"/>

SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
3. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
4. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
5. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
6. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
7. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
8. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
9. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
10. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
11. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
(Date:8/26/2014)... -- An analysis by Replikins, Ltd. of Pubmed data ... virus strains has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
(Date:8/26/2014)... argument has just been added to the growing ... as the next big thing in the high-tech ... materials. An international collaboration of researchers led by ... (DOE),s Lawrence Berkeley National Laboratory (Berkeley Lab) has ... transfer in photo-excited MX2 materials. The recorded charge ...
(Date:8/26/2014)... Aug. 26, 2014  ViveBio, LLC a leading ... stabilization and transportation, announced today that it has ... LLC (LPS) of Knoxville, Tennessee ... the United States . ViveST ... ambient temperature dried biological specimen transport systems.  The ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Competition for graphene 2ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2
... YORK, Oct 6 NeoStem, Inc. (NYSE Amex: NBS ... storage of adult stem cells for future medical need and ... Technology that uses very small embryonic-like stem cells isolated from ... a grant of $108,746 for the repair of bone defects ...
... ... the Broad Institute,s NIH-funded Molecular Libraries and Imaging Initiative , ... Lexington, Mass. (USA) and Basel, Switzerland (PRWEB) ... for pharmaceutical R&D and related life sciences, today announced that the Broad Institute of ...
... MELBOURNE, Australia, Oct. 5 Cytopia Limited (ASX: CYT) ... BioSciences Inc. ("YM") have signed an exclusive and binding ... YM will acquire all of the issued shares and ... scheme(s) of arrangement ("Scheme(s)") and shareholders (and optionholders if ...
Cached Biology Technology:NeoStem, Inc. Awarded NIH Research and Research Infrastructure 'Grand Opportunities' Grant 2NeoStem, Inc. Awarded NIH Research and Research Infrastructure 'Grand Opportunities' Grant 3Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 2Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 3Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 4Cytopia Merger with Toronto-based YM BioSciences Inc. 2Cytopia Merger with Toronto-based YM BioSciences Inc. 3Cytopia Merger with Toronto-based YM BioSciences Inc. 4Cytopia Merger with Toronto-based YM BioSciences Inc. 5Cytopia Merger with Toronto-based YM BioSciences Inc. 6Cytopia Merger with Toronto-based YM BioSciences Inc. 7
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
(Date:8/27/2014)... The IEEE Engineering in Medicine and Biology Society (EMBS) ... (EMBC,14), this year being held at the Sheraton Chicago ... , from Tuesday, August 26 through Saturday, August 30. ... in science, medicine, and engineering are registered to attend. ... This year,s conference theme is Discovering, Innovating, ...
(Date:8/27/2014)... are often depicted as giant, frightening beasts. But every ... of a rock slab containing fossils of 24 very ... a group of hatchlings overseen by a caretaker, according ... , Penn,s Brandon P. Hedrick and Peter Dodson led ... of Natural History, where the specimen is held. Hedrick ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3
... enzyme that naturally produces alkanes -- long carbon-chain molecules ... in gasoline -- have figured out why the natural ... with that knowledge, they,ve devised a strategy to keep ... at the U.S. Department of Energy,s Brookhaven National Laboratory ...
... boost of activity at the back of the ... patients would respond to an experimental rapid-acting antidepressant, ... "We have discovered a potential ... treatment selection by revealing brain-based differences between patients," ...
... MD The Federation of American Societies for Experimental ... Science Research Conference (SRC): NAD Metabolism & Signaling. ... NAD and related metabolites are involved in a wide ... diseases, including type 2 diabetes and other metabolic complications. ...
Cached Biology News:Scientists turn toxic by-product into biofuel booster 2Scientists turn toxic by-product into biofuel booster 3Imaging biomarker predicts response to rapid antidepressant 2Imaging biomarker predicts response to rapid antidepressant 3FASEB SRC announces conference registration open for: NAD Metabolism & Signaling 2
... Once a macromolecular structure has been determined, ... to a widely diverse audience of scientists, ... printed literature and dissemination over the Internet, ... personal web pages. Printed literature has the ...
... 45° Fixed Angle Rotor ... Centra CL2, Centra CL3CL3R, and ... concentration of sputum samples and ... samples. Provides individual aerosol containment. ...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Buckets for tube holder inserts...
Biology Products: